Welcome to our dedicated page for Fibrogen SEC filings (Ticker: FGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FibroGen鈥檚 10-K isn鈥檛 just long鈥攊t鈥檚 layered with clinical data, collaboration accounting, and patent tables that can overwhelm even seasoned analysts. Pinpointing when a Phase 3 trial might impact revenue or why deferred payments surged requires hours of line-by-line reading.
Stock Titan turns that challenge into a three-minute scan. Our AI produces clear, section-by-section summaries, so understanding FibroGen SEC documents with AI feels straightforward. Want the highlight reel from the latest FibroGen quarterly earnings report 10-Q filing? We flag new trial costs and cash-runway updates. Need FibroGen Form 4 insider transactions real-time? Instant alerts show executive buys and sells, giving context around data-release dates. Every filing鈥�10-K, 10-Q, 8-K, S-8, or DEF 14A鈥攊s posted within minutes of hitting EDGAR and paired with concise commentary.
Here鈥檚 how professionals use the page:
- Track FibroGen insider trading Form 4 transactions before pivotal readouts.
- Compare R&D spend trends with our FibroGen earnings report filing analysis.
- See partnership milestone revenue explained inside an FibroGen 8-K material events explained digest.
- Review pay packages via the FibroGen proxy statement executive compensation breakdown.
- Dive into pipeline risk factors with the FibroGen annual report 10-K simplified summary.
- Monitor FibroGen executive stock transactions Form 4 to gauge insider sentiment.
Whether you鈥檙e a buy-side analyst modeling cash burn or a physician-investor following antibody-drug conjugate progress, our platform delivers the insight you need鈥攚ithout wading through 200-page PDFs. FibroGen SEC filings explained simply starts here.
FibroGen, Inc. reported condensed consolidated results for the quarter ended June 30, 2025. Total assets were $178.1 million versus $214.5 million at year-end 2024, and the company reported a consolidated total deficit of $202.5 million. For continuing operations, total revenue was $1.35 million for the quarter and $4.09 million for the six months ended June 30, 2025. The company recorded a net loss of $7.6 million for the quarter and $3.0 million for the six-month period; income from discontinued operations was $6.08 million for the quarter and $27.49 million for six months.
The company entered a share purchase agreement to sell FibroGen International to AstraZeneca for $85 million plus the net cash in China, with closing expected in the third quarter of 2025 subject to China SAMR approval. Management disclosed substantial doubt about the company鈥檚 ability to continue as a going concern without closing the sale or obtaining additional financing and must satisfy a U.S. cash covenant of $18.75 million. The company has a $75 million senior secured term loan (principal) that is presented as current with maturity in May 2026 and a liability related to the sale of future revenues of approximately $63.0 million.
FAQ
What is the current stock price of Fibrogen (FGEN)?
What is the market cap of Fibrogen (FGEN)?
